Literature DB >> 11251382

Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA.

S Manam1, B J Ledwith, A B Barnum, P J Troilo, C J Pauley, L B Harper, T G Griffiths , Z Niu, L Denisova, T T Follmer, S J Pacchione, Z Wang, C M Beare, W J Bagdon, W W Nichols.   

Abstract

A variety of factors could affect the frequency of integration of plasmid DNA vaccines into host cellular DNA, including DNA sequences within the plasmid, the expressed gene product (antigen), the formulation, delivery method, route of administration, and the type of cells exposed to the plasmid. In this report, we examined the tissue distribution and potential integration of plasmid DNA vaccines following intramuscular administration in mice and guinea pigs. We compared needle versus Biojector (needleless jet) delivery, examined the effect of aluminum phosphate adjuvants, compared the results of different plasmid DNA vaccines, and tested a gene (the human papilloma virus E7 gene) whose protein product is known to increase integration frequency in vitro. Six weeks following intramuscular injection, the vast majority of the plasmid was detected in the muscle and skin near the injection site; lower levels of plasmid were also detected in the draining lymph nodes. At early time points (1-7 days) after injection, a low level of systemic exposure could be detected. Occasionally, plasmid was detected in gonads, but it dissipated rapidly and was extrachromosomal - indicating a low risk of germline transmission. Aluminum phosphate adjuvant had no effect on the tissue distribution and did not result in a detectable increase in integration frequency. Biojector delivery, compared with needle injection, greatly increased the uptake of plasmid (particularly in skin at the injection site), but did not result in a detectable increase in integration frequency. Finally, injection of a plasmid DNA vaccine containing the human papilloma virus type 16 E7 gene, known to increase integration in vitro, did not result in detectable integration in mice. These results suggest that the risk of integration following intramuscular injection of plasmid DNA is low under a variety of experimental conditions. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11251382     DOI: 10.1159/000053994

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  37 in total

Review 1.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

2.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA.

Authors:  Juergen Mairhofer; Reingard Grabherr
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

4.  Investigation of DNA integration into reproductive organs following intramuscular injection of DNA in mice.

Authors:  Fatemeh Vahedi; Najmeh Nazari; Shirin Arbabi; Yasser Peymanfar
Journal:  Rep Biochem Mol Biol       Date:  2012-10

5.  Detection of anatid herpesvirus 1 gC gene by TaqMan fluorescent quantitative real-time PCR with specific primers and probe.

Authors:  Qing Zou; Kunfeng Sun; Anchun Cheng; Mingshu Wang; Chao Xu; Dekang Zhu; Renyong Jia; Qihui Luo; Yi Zhou; Zhengli Chen; Xiaoyue Chen
Journal:  Virol J       Date:  2010-02-13       Impact factor: 4.099

Review 6.  FDA guidance on prophylactic DNA vaccines: analysis and recommendations.

Authors:  Dennis M Klinman; Sven Klaschik; Debra Tross; Hidekazu Shirota; Folkert Steinhagen
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

Review 7.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

8.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

Review 9.  Molecular-genetic imaging of cancer.

Authors:  Il Minn; Mitchell E Menezes; Siddik Sarkar; Keerthi Yarlagadda; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher; Martin G Pomper
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

10.  A detailed characterisation of the distribution and presentation of DNA vaccine encoded antigen.

Authors:  Catherine M Rush; Timothy J Mitchell; Paul Garside
Journal:  Vaccine       Date:  2009-12-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.